Morgan Stanley upgraded ResMed from Equal-Weight to Overweight and set a new price target of $169.00 from $180.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/24/2024 | $280.00 | Outperform | Robert W. Baird |
| 9/18/2024 | $180.00 | Peer Perform → Underperform | Wolfe Research |
| 9/4/2024 | Buy → Hold | Needham | |
| 6/25/2024 | Outperform → Perform | Oppenheimer | |
| 6/24/2024 | Buy → Neutral | Citigroup | |
| 2/6/2024 | $227.00 | Overweight | KeyBanc Capital Markets |
| 10/27/2023 | $180.00 → $169.00 | Equal-Weight → Overweight | Morgan Stanley |
| 10/12/2023 | $273.00 → $202.00 | Outperform → Sector Perform | RBC Capital Mkts |
DelOrefice is the Chief Financial Officer at BD, one of the largest global MedTech companies in the worldBoard appointment brings over 30 years of strategic and operational finance expertise SAN DIEGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed's regularly scheduled board meeting on August 15, 2024, and will stand for re-election with the rest of ResMed's directors at its annual meeting on November 21, 2024. Mr. DelOrefice has also been appointed as a member of ResMed's board au
Rider and Haake, both internal promotions, joined ResMed's executive team on May 1Rider, currently Senior Vice President, Deputy Global General Counsel will succeed retiring Chief Administrative Officer, Global General Counsel, and Secretary David Pendarvis on July 1 SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced the appointment of two new executive team members: Michael Rider, Global General Counsel & Secretary, effective July 1, 2023, and Dawn Haake as ResMed's first Chief Quality Officer, effective May 1, 2023. Both joined ResMed's executive team on May 1 and report to the Office of the CEO. Michael Rider was selected following a previously a
SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced ResMed's board of directors has appointed chief executive officer Michael ("Mick") Farrell as chair of the board, effective January 25, 2023. Mr. Farrell succeeds current chair Peter Farrell who will become chair emeritus and will remain an active board member. Mick Farrell became ResMed's CEO on March 1, 2013, and has served as a member of the company's board of directors since assuming that role. "I am honored to expand my role with ResMed as its next chair and to succeed my dad, Peter Farrell, whose vision, leadership, and guidance have helped ResMed become the largest outside-hospital, digital
Robert W. Baird initiated coverage of ResMed with a rating of Outperform and set a new price target of $280.00
Wolfe Research downgraded ResMed from Peer Perform to Underperform and set a new price target of $180.00
Needham downgraded ResMed from Buy to Hold
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
8-K - RESMED INC (0000943819) (Filer)
DEFA14A - RESMED INC (0000943819) (Filer)
10-Q - RESMED INC (0000943819) (Filer)
Issued on behalf of Avant Technologies Inc. USA News Group News Commentary VANCOUVER, BC, Nov. 12, 2024 /PRNewswire/ -- Recently the World Economic Forum released a report that highlights AI's potential to relieve pressure on healthcare systems worldwide, with Mayo Clinic's early adoption showing how AI can drive progress. Elon Musk has also hinted that his company's Grok AI could have applications in medical image analysis. At this year's HLTH conference in Las Vegas, tech giants like Nvidia, Google, and Microsoft presented their latest AI healthcare tools. Meanwhile, a range of emerging tech companies are making strides in AI-powered healthcare, including: Avant Technologies, Inc. (OTCQB:
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 3:30 p.m. (Pacific Standard Time) at the Terranea Resort Hotel in Rancho Palos Verdes, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following t
Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27%Operating cash flow of $326 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended September 30, 2024. First Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 11% to $1.2 billion; up 11% on a constant currency basis Gross margin improved 420 bps to 58.6%; non-GAAP gross margin improved 320 bps to 59.2%Income from operations increased 34%; non-GAAP income from operation
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs cut the price target for SunPower Corporation (NASDAQ:SPWR) from $2 to $0.5. Goldman Sachs analyst Brian Lee maintained a Sell rating. SunPower shares gained 5.4% to close at $0.7158 on Monday. See how other analysts view this stock. Piper Sandler increased the price target for Cathay General Bancorp (NASDAQ:CATY) from $32 to $36. Piper Sandler analyst Matthew Clark maintained an Underweight rating. Cathay General Bancorp shares gained 2.4% to close at $43.02 on Monday. See how other
During the last three months, 6 analysts shared their evaluations of ResMed (NYSE:RMD), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 2 0 0 Last 30D 0 0 1 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 2 1 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $219.0, with a high estimate of $238.00 and a low estimate of $200.00. This upward trend is apparent, with the
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $200 to $204.
Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27%Operating cash flow of $326 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended September 30, 2024. First Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 11% to $1.2 billion; up 11% on a constant currency basis Gross margin improved 420 bps to 58.6%; non-GAAP gross margin improved 320 bps to 59.2%Income from operations increased 34%; non-GAAP income from operation
SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: http://investor.resmed.com Date: Thursday, October 24, 2024 Time: 1:30 p.m. PDT / 4:30 p.m. EDT International: London, Thursday, October 24, 2024, 9:30 p.m. BSTSydney, Friday, October 25, 2024, 7:30 a.m.
Year-over-year revenue grows 9%, operating profit up 38%, non-GAAP operating profit up 30%Operating cash flow of $440 millionQuarterly dividend increases 10% to $0.53 per shareCompany to host an Investor Day on September 30, 2024 Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended June 30, 2024. Fourth Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 9% to $1.2 billion; up 10% on a constant currency basis Gross margin improved 350 bps to 58.5%; non-GAAP gross ma
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)